The Salmeterol Xinafoate Inhalation, cataloged under National Stock Number 6505-01-388-9515, is classified within Federal Supply Class 6505 (Drugs and Biologicals) of the Medical, Dental, and Veterinary Equipment group. The manufacturer of record is Glaxo Wellcome Inc. Government technical data includes 1 specification, cited from the U.S. Government catalog. The record lists 2 manufacturer part numbers for this item, enabling identification through both NSN and commercial part number lookups. 4 additional reference documents (drawings, advisory and superseded references) are recorded in the U.S. Government catalog. Current acquisition status: Active.
| Parameter | Value |
|---|---|
| NSN | 6505-01-388-9515 |
| Primary Part Number | NDC00173-0467-00 |
| Item Name | Salmeterol Xinafoate Inhalation |
| FSC / FSG | 6505 / 65 — Drugs and Biologicals |
| Manufacturer | Glaxo Wellcome Inc |
| Status | ACTIVE |
| Supplementary Features | SINGLE SIZE; THERAPEUTICALLY EQUIVALENT TO SEREVENT BY GLASO INC.; 60 DOSE INSTITUTIONAL PG |
| Acquisition Status | ACTIVE |
| DEMIL Code | DEMIL A — No Demilitarization Required |
| Hazard | Possible hazard — SDS may be required (DLA HMIC P) |
| Criticality Code | X |
| Part Number | Manufacturer |
|---|---|
| SEREVENT DISKUS 50MCG 60 DOSES | Glaxosmithkline Pharmaceuticals (BEL) |
| NDC00173-0467-00 PRIMARY | Glaxo Wellcome Inc (USA) |
| Reference | Meaning |
|---|---|
| SEREVENT INHALATION AEROSOL | 5/1 Secondary reference Glaxo Wellcome Inc |
| 1221514 | 6/9 Informative reference only Association Pharmaceutique Belge-Algemene Pharmaceutische Bond |
| R03AC12 | 6/9 Informative reference only Who Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health |
| SEREVENT | 5/1 Secondary reference Glaxo Wellcome Inc |
NSN 6505-01-388-9515 is a Salmeterol Xinafoate Inhalation, manufactured by Glaxo Wellcome Inc, classified under FSC 6505, Drugs and Biologicals. Status: active.
NSN 6505-01-388-9515 has 2 manufacturer part numbers on file: SEREVENT DISKUS 50MCG 60 DOSES (Glaxosmithkline Pharmaceuticals), NDC00173-0467-00 (Glaxo Wellcome Inc).
Key specifications for NDC00173-0467-00: Supplementary Features: SINGLE SIZE; THERAPEUTICALLY EQUIVALENT TO SEREVENT BY GLASO INC.; 60 DOSE INSTITUTIONAL PG; Part Name Assigned by Controlling Agency: SALMETEROL XINAFOATE INHALATION AEROSOL 60 DOSES. 1 specification is documented in the U.S. Government catalog.
Possible hazard — SDS may be required (DLA HMIC P). Hazard information on this page is shown exactly as it appears in the DLA record.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-16.
U.S. Government catalog: edition PUBLOGDVD v12.0.0 (OCT 2026), edition date 2026-10-01, retrieved 2026-10-18.